News Health & Medicine

The weight-loss drug Wegovy lowered heart attack risk in a large trial

Weekly injections of the medication cut the number of serious heart problems 

An image shows four Wegovy injector pens lying in a white cardboard box.

Results from a new clinical trial suggest that weekly injections of Wegovy can lower the risk of serious heart problems in some adults.

Michael Siluk/Alamy Stock Photo

By Meghan Rosen

PHILADELPHIA ­— At the recent American Heart Association meeting, a cavernous room full of doctors erupted into applause. Cleveland Clinic cardiologist A. Michael Lincoff had just presented the dramatic — and at times enigmatic — results of a new clinical trial on the weight-loss drug semaglutide.